News | Peripheral Artery Disease (PAD) | May 20, 2022

New Longterm Data of Paclitaxel Devices Continues to Show No Increased Mortality Compared to Non-drug Coated Devices

Data Extending through Six Years from the SAFE-PAD Study Presented as Late-Breaking Clinical Research

Three years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at SCAI22.

Three years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at SCAI22.


May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD) study were presented as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions. The analysis found no meaningful difference in survival between patients treated with a paclitaxel drug-coated device (DCD) and those treated with a non-drug coated device (NDCD) for up to six years after the index procedure, regardless of the patient’s mortality risk and device type.

Peripheral vascular intervention is used to treat patients with symptomatic peripheral artery disease (PAD), a condition in which the vessels that carry block from the heart to the legs becomes narrowed or blocked (CDC) and impacts 6.5 million people in the United States (AHA). Paclitaxel-coated peripheral devices were considered the stand-of-care when treating PAD patients due to the decreased need for revascularization, a common risk of peripheral vascular intervention. 

However, a 2018 meta-analysis found paclitaxel-coated peripheral devices were associated with increased mortality, drawing into question the safety of these devices. The SAFE-PAD study was created in collaboration with the Food & Drug Administration to evaluate the long-term safety of paclitaxel-coated devices compared with non-paclitaxel-coated devices for femoropopliteal artery revascularization among a broad, real-world population of patients with peripheral artery disease.

The study included Medicare beneficiaries ≥66 years treated with a DCD or NDCD from 4/1/2015-12/31/2018. Non-inferiority between devices was evaluated for mortality through 7/21/2021. A number of pre-specified subgroups, including a cohort at the lowest risk of mortality defined as those aged 66-70 with no critical limb ischemia and ≤2 comorbidities, were evaluated.

“Our goal is to give patients the most durable treatment possible that will keep them out of the hospital and living their lives. Patients with PAD tend to be of lower socioeconomic status, more likely to be underserved minority populations and often need to travel long distances or take time off work to seek treatment,” said Eric Secemsky, Director of Vascular Intervention at Beth Israel Deaconess Medical Center, Section Head of Interventional Cardiology and Vascular Research at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology and Assistant Professor of Medicine at Harvard Medical School. “Not having access to important treatment options known to reduce the risk of repeat intervention can have a substantial influence on our PAD patients, ultimately impacting their outcomes and quality of life. The findings presented today add to the growing body of evidence showing these devices are safe for use.” 

Of 168,553 patients, 70,584 (41.9%) were treated with a DCD. Median follow-up was 3.52 years. The weighted cumulative incidence of mortality at 6.3 years was 63.6% with NDCDs and 62.5% with DCDs (p<0.0001). Findings were consistent among all subgroups. In particular, there was no difference in risk among those at lowest risk of mortality (n=4,212; weighted HR 0.98; 95%CI 0.87, 1.10).

Researchers note that were will future several reports from the SAFE-PAD study with a final report published in the next two years.

For more information: www.scai.org

Find more SCAI22 coverage here

 

Related Paclitaxel Safety Content:

SAFE-PAD Study Shows No Safety Issues With Paclitaxel-coated Devices In Peripheral Artery Disease

No Increased Long-Term Mortality for the Paclitaxel-Coated Zilver PTX Stent 

FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

No Increased Long-Term Mortality for the Paclitaxel-Coated Zilver PTX Stent

FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents

Top 10 Takeaways on Interventional Technologies at TCT 2020

No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease

FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices

 

Safety of Paclitaxel-eluting Stents and Balloons Called Into Question

6 Hot Topics in Interventional Cardiology at TCT 2019

The Data-driven Crises Involving Paclitaxel and Impella RP

VIDEO: SCAI Prospective on Key Takeaways at TCT 2019


Related Content

News | SCAI

May 10, 2022 — After two years of virtual meetings, the Society for Cardiovascular Angiography & Interventions (SCAI) ...

Home May 10, 2022
Home
Feature | SCAI

May 21, 2020 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 21, 2020
Home
News | SCAI

May 17, 2020 – A new study shows that when compared with patients without intermediate left main coronary artery disease ...

Home May 17, 2020
Home
News | SCAI

May 17, 2020 — Cindy Grines, M.D., MSCAI, a world-renowned physician credited for pioneering percutaneous coronary ...

Home May 17, 2020
Home
Feature | SCAI

May 8, 2019 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions will take ...

Home May 08, 2019
Home
Feature | SCAI | Subhash Banerjee, M.D., FSCAI, Abu-Fadel Mazen, M.D., FSCAI and Rajesh Swaminathan, M.D., FSCAI

The Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions in Las Vegas, May 19-22 ...

Home February 25, 2019
Home
Feature | SCAI

Here is an aggregation of all the news and late-breaking studies presented at the 2018 Society for Cardiovascular ...

Home May 14, 2018
Home
Feature | SCAI

May 30, 2017 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions took place ...

Home May 01, 2017
Home
Subscribe Now